TW200635584A - Use of PPAR agonists for the treatment of congestive heart failure - Google Patents

Use of PPAR agonists for the treatment of congestive heart failure

Info

Publication number
TW200635584A
TW200635584A TW094144376A TW94144376A TW200635584A TW 200635584 A TW200635584 A TW 200635584A TW 094144376 A TW094144376 A TW 094144376A TW 94144376 A TW94144376 A TW 94144376A TW 200635584 A TW200635584 A TW 200635584A
Authority
TW
Taiwan
Prior art keywords
treatment
heart failure
congestive heart
ppar agonists
ppar
Prior art date
Application number
TW094144376A
Other languages
English (en)
Chinese (zh)
Inventor
Wolfagng Linz
Stefan Schaefer
Eugen Falk
Hans-Ludwig Schaefer
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of TW200635584A publication Critical patent/TW200635584A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
TW094144376A 2004-12-17 2005-12-15 Use of PPAR agonists for the treatment of congestive heart failure TW200635584A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04029946A EP1671633A1 (en) 2004-12-17 2004-12-17 Use of PPAR agonists for the treatment of congestive heart failure

Publications (1)

Publication Number Publication Date
TW200635584A true TW200635584A (en) 2006-10-16

Family

ID=34927823

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094144376A TW200635584A (en) 2004-12-17 2005-12-15 Use of PPAR agonists for the treatment of congestive heart failure

Country Status (16)

Country Link
US (1) US7601863B2 (cg-RX-API-DMAC7.html)
EP (2) EP1671633A1 (cg-RX-API-DMAC7.html)
JP (1) JP2008524129A (cg-RX-API-DMAC7.html)
KR (1) KR20070086332A (cg-RX-API-DMAC7.html)
CN (1) CN101072557A (cg-RX-API-DMAC7.html)
AR (1) AR051723A1 (cg-RX-API-DMAC7.html)
AT (1) ATE498400T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005315920A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0519661A2 (cg-RX-API-DMAC7.html)
CA (1) CA2590391A1 (cg-RX-API-DMAC7.html)
DE (1) DE602005026443D1 (cg-RX-API-DMAC7.html)
IL (1) IL183810A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007006678A (cg-RX-API-DMAC7.html)
MY (1) MY141010A (cg-RX-API-DMAC7.html)
TW (1) TW200635584A (cg-RX-API-DMAC7.html)
WO (1) WO2006063715A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399777B2 (en) 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
HUE055678T2 (hu) 2016-10-05 2021-12-28 Mitobridge Inc PPAR agonista vegyületek kristályos és só alakjai

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE368037T1 (de) * 1999-04-28 2007-08-15 Sanofi Aventis Deutschland Di-aryl-säurederivate als ppar rezeptor liganden
RU2330846C2 (ru) * 2001-08-31 2008-08-10 Санофи-Авентис Дойчланд Гмбх Диарилциклоалкильные производные, способ их получения и их применение в качестве ppar-активаторов
WO2004082621A2 (en) * 2003-03-15 2004-09-30 Bethesda Pharmaceuticals, Inc. Novel ppar agonists, pharmaceutical compositions and uses thereof
US6989462B2 (en) * 2003-03-25 2006-01-24 Sanofi-Aventis Deutschland Gmbh Synthesis of 2-chloromethyl-6-methylbenzoic ester
US6987118B2 (en) * 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators

Also Published As

Publication number Publication date
US7601863B2 (en) 2009-10-13
MX2007006678A (es) 2007-08-14
CN101072557A (zh) 2007-11-14
BRPI0519661A2 (pt) 2009-03-03
CA2590391A1 (en) 2006-06-22
WO2006063715A1 (en) 2006-06-22
MY141010A (en) 2010-02-25
JP2008524129A (ja) 2008-07-10
ATE498400T1 (de) 2011-03-15
DE602005026443D1 (de) 2011-03-31
IL183810A0 (en) 2007-10-31
AU2005315920A1 (en) 2006-06-22
KR20070086332A (ko) 2007-08-27
EP1671633A1 (en) 2006-06-21
US20080039512A1 (en) 2008-02-14
EP1827425B1 (en) 2011-02-16
EP1827425A1 (en) 2007-09-05
AR051723A1 (es) 2007-01-31

Similar Documents

Publication Publication Date Title
GEP20084499B (en) USE OF INTERFERON-ß FOR TREATMENT OF RENAL FAILURE
NO20080622L (no) Disykloalkylurea-glukokinase aktivatorer
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
GB2453058A (en) Kinase antagonists
NO20052887D0 (no) Pyridazinonderivater som GSK-3Beta inhibitorer.
DE602005010109D1 (de) 1,1a,5,5a-tetrahydro-3-thia-cyclopropaäaüpentaleneptor-agonisten
EA200701802A1 (ru) Имидазо(1,2-а)пиридиновые соединения в качестве ингибиторов vegf-r2
LTC1830843I2 (lt) Indolidono dariniai, skirti fibrozinių ligų gydymui arba prevencijai
WO2008097561A8 (en) Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
NO20093542L (no) Inhibering av tumormetastase ved hjelp av anti-neuropilin 2-antistoffer
EA200701845A1 (ru) Рофлумиласт для лечения сахарного диабета
EA201000258A1 (ru) Новые гербициды
CL2007002388A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas.
MX2007008723A (es) Polipeptidos de yersinia spp y metodos de uso.
TW200619206A (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
SE0301650D0 (sv) Novel compounds
EA201000069A1 (ru) Новые гербициды
UA85505C2 (en) Kinase inhibitors
MX2010001303A (es) Compuestos terapeuticos.
MX2007008158A (es) Tratamiento de trastornos por el virus de hepatitis c.
PT2366393E (pt) Roflumilaste para o tratamento da hipertensão pulmonar
WO2005117543A3 (en) N-sulfonylcarboximidamide apoptosis promoters
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
DK2845594T3 (da) Anvendelse af dihydroimidazoloner til behandlingen af hunde.